← Back to patent-cliff list
可利霉素
Tier C — Watch / tradeCarrimycin
北京首科集团有限公司
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：50S ribosomal subunit
Brand：必特
Indications (approved)：细菌感染
Regional status
US
终止
2021-03-30
EU
终止
2021-03-30
China
批准上市
2019-06-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Carrimycin?
Approved indications include: 细菌感染.
When does the Carrimycin patent expire?
No public expiry year is available for Carrimycin yet; this page updates once verified.
How do I get a quote for Carrimycin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24